Creating novel therapeutics together
We will constantly evaluate partnership opportunities that strategically align with our commercial goals, which includes entering into partnerships with multinational pharmaceutical companies to maximise the commercial value of our clinical assets. We will maintain our optionality in terms of the point at which we partner a specific clinical asset and will seek, where appropriate, to retain commercial rights for selected assets.
In addition, we will enter into earlier stage partnerships with pharmaceutical and biotechnology companies, thereby exploiting Kymab’s innovative technology. We approach potential collaborations with a creative foundation and are open to transaction structures which provide our partners the opportunity to accelerate the development of new therapies, whilst retaining value and generating revenues for Kymab’s shareholders. Our strategy is to combine our IntelliSelect™ antibody discovery capabilities with partners possessing world-leading scientific and medical expertise and novel technological capabilities.
We collaborate with the Gates Foundation and its partners on vaccine discovery and development
Combining our complementary expertise to target G-protein-coupled receptors